Methyclothiazide

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Oct 21, 1960	EnduronNDA 12524 · New molecular entity	Abbvie	7	Discontinued
Sep 7, 1977	AquatensenNDA 17364 · New formulation or manufacturer	Medpointe Pharm Hlc	10	Discontinued
May 18, 1982	MethyclothiazideANDA 87786	Ivax Pharms	1	Discontinued
Jun 3, 1982	MethyclothiazideANDA 87913	Ivax Pharms	11	Discontinued
Aug 17, 1982	MethyclothiazideANDA 87672	Pharmobedient	6	Discontinued
Sep 6, 1984	MethyclothiazideANDA 88724	Watson Labs	11	Discontinued
Sep 6, 1984	MethyclothiazideANDA 88750	Watson Labs	1	Discontinued
Feb 12, 1986	MethyclothiazideANDA 89135	Par Pharm	5	Discontinued
Feb 12, 1986	MethyclothiazideANDA 89136	Par Pharm	5	Discontinued
Aug 18, 1988	MethyclothiazideANDA 89835	Chartwell Rx	3	Discontinued
Aug 18, 1988	MethyclothiazideANDA 89837	Chartwell Rx	3	Discontinued
—	MethyclothiazideANDA 85476	Watson Labs	0	Discontinued
—	MethyclothiazideANDA 85487	Watson Labs	0	Discontinued
—	MethyclothiazideANDA 87671	Mylan	0	Discontinued
—	MethyclothiazideANDA 88745	Usl Pharma	0	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA